Next Article in Journal
Non-Melanoma Skin Cancer Mortality in Spain: A Predictive Model up to 2044
Next Article in Special Issue
How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study
Previous Article in Journal
Association of Insulin Resistance with Vascular Ageing in a General Caucasian Population: An EVA Study
Previous Article in Special Issue
Long-Term Outcome in Systemic Lupus Erythematosus; Knowledge from Population-Based Cohorts
 
 
Article
Peer-Review Record

Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry

J. Clin. Med. 2021, 10(24), 5749; https://doi.org/10.3390/jcm10245749
by Víctor Moreno-Torres 1,*, Carlos Tarín 2, Guillermo Ruiz-Irastorza 3, Raquel Castejón 1, Ángela Gutiérrez-Rojas 1, Ana Royuela 4, Pedro Durán-del Campo 1, Susana Mellor-Pita 1, Pablo Tutor 1, Silvia Rosado 1, Enrique Sánchez 1, María Martínez-Urbistondo 1, Carmen de Mendoza 1, Miguel Yebra 1 and Juan-Antonio Vargas 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2021, 10(24), 5749; https://doi.org/10.3390/jcm10245749
Submission received: 22 November 2021 / Revised: 3 December 2021 / Accepted: 6 December 2021 / Published: 8 December 2021

Round 1

Reviewer 1 Report

I would like to congratulate the authors on their exellent work. 

I found only two small fault: 

89th row: you wrote 83.1 % but 83.3 % is in table 1. 

You write about the overall mortality in row 128-130, but these date are not included in table 3.  

Author Response

Thank you very much for your comments.

  1. Indeed, 83.3% patients were female. This has been corrected.
  2. The mortality rate for each group and period has been added to the table.

Reviewer 2 Report

The authors described admission and death causes of SLE patients in large number of SLE patients from Spain (99,859,25 admissions from 43,432 patients with SLE). They have pointed out that cardiovascular disease (CVD), infections and neoplasm have become main causes of admissions and mortality. The information provided is informative and beneficial for readers. It will add more data from different region of the world and help the clinicians to follow-up their SLE patients.  

Only minor points I would like to add.

  1. Could it possible to clarify the type of solid tumor among SLE individuals?
  2. table 2, the age shown is 379. I assume that it is a typo.

Author Response

Thank you very much for your comments.

1. We agree with the reviewer. While this information could possible to include, its extension and implications would probably excess the present manuscript length and objectives. In fact, we are performing a new and more profound analysis regarding neoplasms in SLE, since, as it was pointed out, cancer should be also considered a long-term complication of SLE.

2. The mean age for this period was 37.9 years-old. This has been corrected.

Back to TopTop